Identification of Jun Loss Promotes Resistance to Histone Deacetylase Inhibitor Entinostat Through Myc Signaling in Luminal Breast Cancer

Overview

Journal Genome Med

Publisher Biomed Central

Specialty Genetics

Date 2018 Dec 1

PMID 30497520

Citations 6

Authors

Maki Tanioka

Kevin R Mott

Daniel P Hollern

Cheng Fan

David B Darr

Charles M Perou

Affiliations

Soon will be listed here.

Abstract

Background: Based on promising phase II data, the histone deacetylase inhibitor entinostat is in phase III trials for patients with metastatic estrogen receptor-positive breast cancer. Predictors of sensitivity and resistance, however, remain unknown.

Methods: A total of eight cell lines and nine mouse models of breast cancer were treated with entinostat. Luminal cell lines were treated with or without entinostat at their IC doses, and MMTV/Neu luminal mouse tumors were untreated or treated with entinostat until progression. We investigated these models using their gene expression profiling by microarray and copy number by arrayCGH. We also utilized the network-based DawnRank algorithm that integrates DNA and RNA data to identify driver genes of resistance. The impact of candidate drivers was investigated in The Cancer Genome Atlas and METABRIC breast cancer datasets.

Results: Luminal models displayed enhanced sensitivity to entinostat as compared to basal-like or claudin-low models. Both in vitro and in vivo luminal models showed significant downregulation of Myc gene signatures following entinostat treatment. Myc gene signatures became upregulated on tumor progression in vivo and overexpression of Myc conferred resistance to entinostat in vitro. Further examination of resistance mechanisms in MMTV/Neu tumors identified a portion of mouse chromosome 4 that had DNA copy number loss and low gene expression. Within this region, Jun was computationally identified to be a driver gene of resistance. Jun knockdown in cell lines resulted in upregulation of Myc signatures and made these lines more resistant to entinostat. Jun-deleted samples, found in 17-23% of luminal patients, had significantly higher Myc signature scores that predicted worse survival.

Conclusions: Entinostat inhibited luminal breast cancer through Myc signaling, which was upregulated by Jun DNA loss to promote resistance to entinostat in our models. Jun DNA copy number loss, and/or high MYC signatures, might represent biomarkers for entinostat responsiveness in luminal breast cancer.

Citing Articles

Jun, an Oncological Foe or Friend?.

Jafri Z, Li Y, Zhang J, OMeara C, Khachigian L Int J Mol Sci. 2025; 26(2).

PMID: 39859271 PMC: 11766113. DOI: 10.3390/ijms26020555.

Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy.

Clements M, Holtslander L, Johnson J, Johnson R JBMR Plus. 2023; 7(3):e10694.

PMID: 36936362 PMC: 10020917. DOI: 10.1002/jbm4.10694.

Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study.

Thennavan A, Garcia-Recio S, Liu S, He X, Perou C NPJ Breast Cancer. 2022; 8(1):83.

PMID: 35851387 PMC: 9293914. DOI: 10.1038/s41523-022-00450-w.

MYC Activity Inference Captures Diverse Mechanisms of Aberrant MYC Pathway Activation in Human Cancers.

Schaafsma E, Zhao Y, Zhang L, Li Y, Cheng C Mol Cancer Res. 2020; 19(3):414-428.

PMID: 33234576 PMC: 7925347. DOI: 10.1158/1541-7786.MCR-20-0526.

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.

Hellmann M, Janne P, Opyrchal M, Hafez N, Raez L, Gabrilovich D Clin Cancer Res. 2020; 27(4):1019-1028.

PMID: 33203644 PMC: 7887114. DOI: 10.1158/1078-0432.CCR-20-3305.

References

Weigman V, Chao H, Shabalin A, He X, Parker J, Nordgard S . Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2011; 133(3):865-80. PMC: 3387500. DOI: 10.1007/s10549-011-1846-y. View

Zhu P, Martin E, Mengwasser J, Schlag P, Janssen K, Gottlicher M . Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004; 5(5):455-63. DOI: 10.1016/s1535-6108(04)00114-x. View

Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi G, Ordentlich P . A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 2014; 146(2):259-72. PMC: 4119423. DOI: 10.1007/s10549-014-3014-7. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S . Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin Cancer Res. 2017; 23(17):5187-5201. PMC: 5723438. DOI: 10.1158/1078-0432.CCR-17-0741. View

Baselga J, Campone M, Piccart M, Burris 3rd H, Rugo H, Sahmoud T . Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2011; 366(6):520-9. PMC: 5705195. DOI: 10.1056/NEJMoa1109653. View

Adhikary S, Eilers M . Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005; 6(8):635-45. DOI: 10.1038/nrm1703. View

Vaque J, Fernandez-Garcia B, Garcia-Sanz P, Ferrandiz N, Bretones G, Calvo F . c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation. Mol Cancer Res. 2008; 6(2):325-39. DOI: 10.1158/1541-7786.MCR-07-0180. View

Herschkowitz J, Simin K, Weigman V, Mikaelian I, Usary J, Hu Z . Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007; 8(5):R76. PMC: 1929138. DOI: 10.1186/gb-2007-8-5-r76. View

10.

Gatza M, Lucas J, Barry W, Kim J, Wang Q, Crawford M . A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010; 107(15):6994-9. PMC: 2872436. DOI: 10.1073/pnas.0912708107. View

11.

Labisso W, Wirth M, Stojanovic N, Stauber R, Schnieke A, Schmid R . MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle. 2012; 11(8):1593-602. DOI: 10.4161/cc.20008. View

12.

Lin C, Loven J, Rahl P, Paranal R, Burge C, Bradner J . Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012; 151(1):56-67. PMC: 3462372. DOI: 10.1016/j.cell.2012.08.026. View

13.

Tanioka M, Fan C, Parker J, Hoadley K, Hu Z, Li Y . Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res. 2018; 24(21):5292-5304. PMC: 6214737. DOI: 10.1158/1078-0432.CCR-17-3431. View

14.

Benedetti R, Conte M, Altucci L . Targeting Histone Deacetylases in Diseases: Where Are We?. Antioxid Redox Signal. 2014; 23(1):99-126. PMC: 4492558. DOI: 10.1089/ars.2013.5776. View

15.

Dang C . MYC on the path to cancer. Cell. 2012; 149(1):22-35. PMC: 3345192. DOI: 10.1016/j.cell.2012.03.003. View

16.

Meyer N, Penn L . Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-90. DOI: 10.1038/nrc2231. View

17.

Troester M, Hoadley K, Sorlie T, Herbert B, Borresen-Dale A, Lonning P . Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004; 64(12):4218-26. DOI: 10.1158/0008-5472.CAN-04-0107. View

18.

Piekarz R, Frye R, Turner M, Wright J, Allen S, Kirschbaum M . Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27(32):5410-7. PMC: 2773225. DOI: 10.1200/JCO.2008.21.6150. View

19.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

20.

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S . Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016; 375(18):1738-1748. DOI: 10.1056/NEJMoa1609709. View